KU-55933 (ATM Kinase Inhibitor)

For research use only. Not for use in humans.

目录号：S1092

KU-55933 (ATM Kinase Inhibitor) Chemical Structure

CAS No. 587871-26-9

KU-55933 (ATM Kinase Inhibitor)是一种有效的，特异性ATM抑制剂，在无细胞试验中IC50/Ki为12.9 nM/2.2 nM，与DNA-PK， PI3K/PI4K， ATR和mTOR相比，对ATM具有高度选择性。KU‑55933 (ATM Kinase Inhibitor)可抑制 autophagy‑initiating kinase ULK1 的激活从而导致自噬的显著减少。

规格 价格 库存 购买数量  
RMB 571.66 现货
RMB 975.88 现货
RMB 3032.31 现货
RMB 7755.93 现货
有超大折扣
大剂量询单有大折扣!

今日订购，明日送达，全国免运费！

全国免费电话：400-668-6834   |   Email：info@selleck.cn

客户使用Selleck生产的KU-55933 (ATM Kinase Inhibitor)发表文献201篇：

产品安全说明书

ATM/ATR抑制剂选择性比较

生物活性

产品描述 KU-55933 (ATM Kinase Inhibitor)是一种有效的，特异性ATM抑制剂，在无细胞试验中IC50/Ki为12.9 nM/2.2 nM，与DNA-PK， PI3K/PI4K， ATR和mTOR相比，对ATM具有高度选择性。KU‑55933 (ATM Kinase Inhibitor)可抑制 autophagy‑initiating kinase ULK1 的激活从而导致自噬的显著减少。
靶点
ATM [1]
(Cell-free assay)
12.9 nM
体外研究

KU-55933是有效的特定ATM抑制剂，IC50为13 nM，Ki值为2.2 nM。KU-55933也抑制DNA-PK和PI3K，IC50分别为2.5和16.6 μM。KU-55933也抑制mTOR活性，IC50为9.3 μM。KU-55933有效作用于ATM依赖的磷酸化作用。KU-55933抑制ATM依赖的磷酸化作用，存在剂量依赖性，IC50为300 nM。小于30 μM时，KU-58050不能抑制p53的ATM-依赖性磷酸化作用（位点为第15位丝氨酸）。在UV-诱导的H2AX（位点为第139位丝氨酸）, NBS1（位点为第343为丝氨酸）, CHK1（位点为第345位丝氨酸）,及SMC1（位点为第966位丝氨酸）中，加入KU-55933没有明显作用效果。紫外处理时，KU-55933切除由电离辐射诱导的ATM磷酸化底物。KU-55933使HeLa细胞对电离辐射敏感。在癌细胞中，KU-55933抑制生长因子诱导的Akt的磷酸化作用。KU-55933抑制癌细胞增殖。KU-55933抑制ATM，通过阻断下游TAp63α的激活，提高存活力。[2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
DU-145 NF7UUGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYXJR|UxRTNwMkezOVIh|ryP NH3TR49USU6JRWK=
HuO-3N1 NVPIbot{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHnKNIhKSzVyPUSuNVcyPDJizszN NIT6dW1USU6JRWK=
LAMA-84 NYjob3BIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYrJR|UxRTRwNUi0OlUh|ryP Mn3IV2FPT0WU
CAL-72 M13i[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXX2eVlTUUN3ME21MlQ5ODh2IN88US=> MXTTRW5ITVJ?
LoVo Mne0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mk\oTWM2OD14LkmzNlM6KM7:TR?= NInXXIpUSU6JRWK=
HH Mne5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGL6OY1KSzVyPUiuNlc3PzFizszN MVnTRW5ITVJ?
SK-MEL-3 NXjYTmRFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4\NTmlEPTB;OD6yPFU4PSEQvF2= NI\MO5FUSU6JRWK=
KM12 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUXudoExUUN3ME25MlIyOTR{IN88US=> NVHudZZpW0GQR1XS
NCI-H1437 NV7LeHprT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1HETWlEPTB;OT64NFk4KM7:TR?= MmXyV2FPT0WU
NCI-H1838 NXO0OHJHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmTCTWM2OD1zMT6xPFY2KM7:TR?= M1rL[XNCVkeHUh?=
J-RT3-T3-5 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUK4e3UxUUN3ME2xNU4zPDF5IN88US=> NHWyWHVUSU6JRWK=
GOTO MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MU\JR|UxRTFzLk[5PVYh|ryP NInh[3BUSU6JRWK=
LB2241-RCC Ml;DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXTJR|UxRTFzLkexPFYh|ryP M3P4WXNCVkeHUh?=
ES7 NGnsTG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mo\QTWM2OD1zMT63PFgh|ryP NILBUIlUSU6JRWK=
KP-N-YS NWnmbHhET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnnrTWM2OD1zMj62N|U1KM7:TR?= M{HXVXNCVkeHUh?=
CAL-12T NHHmXo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYDqTWtIUUN3ME2xN{43OTdizszN Mmi0V2FPT0WU
COLO-684 M3;0[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYPoVlJyUUN3ME2xOE4yPTZ7IN88US=> MoDKV2FPT0WU
DOK M3LhVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVPJR|UxRTF3LkOzNlkh|ryP MWnTRW5ITVJ?
Hs-578-T Mkm0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVTJR|UxRTF3LkSxPFIh|ryP MlHEV2FPT0WU
D-423MG NFu4R3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHf3b3RKSzVyPUG1MlUzOzZizszN MlqzV2FPT0WU
DBTRG-05MG MoqzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWTJR|UxRTF3Lk[xNVEh|ryP NYXRTYVXW0GQR1XS
VM-CUB-1 NGS5NoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGewSJhKSzVyPUG1Mlk5PDlizszN NVrLcXBjW0GQR1XS
KG-1 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYDnOpFTUUN3ME2xOk4xQTl4IN88US=> MkjYV2FPT0WU
8305C MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXLQbFZHUUN3ME2xOk4yQDh7IN88US=> NGG3VHRUSU6JRWK=
HuH-7 NX3yNVJbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYLJR|UxRTF4LkK2O|Qh|ryP NGS5dIhUSU6JRWK=
LXF-289 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWjJR|UxRTF4LkK3OFch|ryP NX\LboQ{W0GQR1XS
NCI-H1793 M3G3PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1\JRWlEPTB;MU[uOFcyOiEQvF2= NXvje4d{W0GQR1XS
ChaGo-K-1 MkjlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVH5NGJ3UUN3ME2xOk43PTZ6IN88US=> MWrTRW5ITVJ?
GCIY M4njSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXfJR|UxRTF4Lke5NFUh|ryP M1PR[HNCVkeHUh?=
SK-MEL-28 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGjvVZlKSzVyPUG3MlA1PzVizszN MVTTRW5ITVJ?
NCI-SNU-1 MkLyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF3PbppKSzVyPUG3MlEzPjlizszN NIG5[ZBUSU6JRWK=
CTB-1 NUDJXJdHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1fRZ2lEPTB;MUeuNlI2QSEQvF2= NWLKdpZYW0GQR1XS
NCI-H82 NUTZV486T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1ft[GlEPTB;MUeuOFU4OyEQvF2= MlLNV2FPT0WU
HCC2998 NWDRc41CT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUWyOmpYUUN3ME2xO{43PzN|IN88US=> NVjIS3d[W0GQR1XS
NCI-H2030 NWrZTnF4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHyyNllKSzVyPUG4MlE6QTdizszN MnvrV2FPT0WU
HuP-T3 NUDoOIRTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHfiSoNKSzVyPUG4MlU5QDhizszN MlnVV2FPT0WU
697 M1X5S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYq1[|NLUUN3ME2xPU4xOjBzIN88US=> NVvRc2s2W0GQR1XS
MLMA NWXiZY5uT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVPJR|UxRTF7LkC1OVch|ryP NUXadJJbW0GQR1XS
HCC70 M3LPOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NULiWlZQUUN3ME2xPU41QDlizszN MXPTRW5ITVJ?
A704 M4PKSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3jIUmlEPTB;MUmuPFMxPSEQvF2= MXTTRW5ITVJ?
D-283MED M3jFV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2D5d2lEPTB;MkCuOVM{QSEQvF2= NIXET4FUSU6JRWK=
U031 M130TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXznenVpUUN3ME2yNU4yPDh7IN88US=> M{DlU3NCVkeHUh?=
HSC-3 Mn:3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUXuO3NmUUN3ME2yNU4yQDN3IN88US=> MnjQV2FPT0WU
JVM-3 NFvTXlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2TtOmlEPTB;MkKuOVA3KM7:TR?= M3m0enNCVkeHUh?=
Mewo Mln5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGK4bm9KSzVyPUKyMlUxPzNizszN NGPSRpRUSU6JRWK=
YH-13 NUnUb2pCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV25cGNbUUN3ME2yNk42OTJ|IN88US=> NV\ibYJ4W0GQR1XS
LB1047-RCC MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{nxbWlEPTB;MkKuOVg4QSEQvF2= MW\TRW5ITVJ?
HCC2157 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWnJR|UxRTJ{LkiwOVQh|ryP NWHxdWllW0GQR1XS
SNU-449 NXj0W4NQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlHPTWM2OD1{Mj64O|Q5KM7:TR?= MYnTRW5ITVJ?
Ramos-2G6-4C10 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX3JR|UxRTJ{Lkm2JO69VQ>? MYDTRW5ITVJ?
CHL-1 MkHiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVXJR|UxRTJ|LkeyPVIh|ryP MVHTRW5ITVJ?
SK-MEL-30 MkS4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NI\obmdKSzVyPUK0MlQ3PjJizszN NIfjT2dUSU6JRWK=
PANC-08-13 MlvYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnX4TWM2OD1{NT6wPVM5KM7:TR?= MVrTRW5ITVJ?
QIMR-WIL MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYnqe5lnUUN3ME2yOU4yQDV6IN88US=> NH7XRmlUSU6JRWK=
BFTC-905 Mlz2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoW4TWM2OD1{NT61PVQ1KM7:TR?= NFrwcJVUSU6JRWK=
GI-1 M2Tzd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYfJR|UxRTJ3LkewOVUh|ryP M2eyeXNCVkeHUh?=
MDA-MB-415 M1:yXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mlz2TWM2OD1{Nj61NFM{KM7:TR?= MorGV2FPT0WU
GT3TKB MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MW\JR|UxRTJ4LkWzOFIh|ryP MWjTRW5ITVJ?
DEL M4T0bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV7JR|UxRTJ4LkizOVYh|ryP NF;mR4dUSU6JRWK=
KOSC-2 M2foUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF3LTIFKSzVyPUK2MlkxPzVizszN NF3EZWdUSU6JRWK=
RVH-421 M{HXXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MY\JR|UxRTJ5LkK5NlEh|ryP NGHYXnlUSU6JRWK=
EW-13 Mor1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVPJR|UxRTJ5LkSzNFgh|ryP M1GxRXNCVkeHUh?=
639-V MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYLvSGZKUUN3ME2yO{42OTF7IN88US=> MUXTRW5ITVJ?
A2780 M3q0WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYrTOow1UUN3ME2yO{43PDFizszN M3G5[HNCVkeHUh?=
SW982 NITvdnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUO3NZlJUUN3ME2yO{46ODV{IN88US=> NV\qWlJNW0GQR1XS
SW1710 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlH4TWM2OD1{OD6wPVgyKM7:TR?= NF\Ce3NUSU6JRWK=
HCC1569 M4LzfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3jOOmlEPTB;MkiuOFg6PyEQvF2= MYHTRW5ITVJ?
MV-4-11 Moq4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEHKTJZKSzVyPUK4MlU4OzVizszN MVfTRW5ITVJ?
BHT-101 M3i2XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH7RPVlKSzVyPUK4MlY2PzJizszN NY\WbGhiW0GQR1XS
Ca9-22 NYfhVpVOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmLoTWM2OD1{OD63NVQh|ryP MnL6V2FPT0WU
HAL-01 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH3lSGtKSzVyPUK4Mlc3OTVizszN MYLTRW5ITVJ?
D-263MG Moe4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGPKO5lKSzVyPUK5MlM1PCEQvF2= MW\TRW5ITVJ?
NEC8 NU[wXG8xT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH;YOZhKSzVyPUK5MlU2PDhizszN NX;aRmoyW0GQR1XS
EKVX NHnme2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYDqSoRtUUN3ME2zNU42QDR5IN88US=> MmrGV2FPT0WU
EM-2 NITBN3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnnLTWM2OD1|MT62N|A1KM7:TR?= NEfibnpUSU6JRWK=
MFM-223 NFXLPZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHP4elhKSzVyPUOxMlgxQThizszN NUjGVFJzW0GQR1XS
SK-PN-DW NUP2b3hqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGnCcnlKSzVyPUOyMlE1ODZizszN NYnNVYxIW0GQR1XS
HuO9 NYXFfWxiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIHYcoRKSzVyPUOyMlUzQDJizszN NYfX[md[W0GQR1XS
MHH-PREB-1 MonDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWrOTIN3UUN3ME2zNk43OjN2IN88US=> MY\TRW5ITVJ?
OVCAR-4 M{\E[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmTWTWM2OD1|Mj64N|Y{KM7:TR?= MofKV2FPT0WU
NCI-H1648 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEfERZFKSzVyPUOyMlg3PTFizszN NGrROmNUSU6JRWK=
MKN1 NEjRNlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4f1U2lEPTB;M{SuNVExOSEQvF2= M2XhSHNCVkeHUh?=
KYSE-450 NHXNe2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoHDTWM2OD1|ND62OFQ1KM7:TR?= NHrTcGNUSU6JRWK=
ES8 MofmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXzJR|UxRTN2Lki5O|Uh|ryP NEC2SYNUSU6JRWK=
MS-1 M4D3UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV\m[VFqUUN3ME2zOE46PTV2IN88US=> NXrMRZBGW0GQR1XS
HOP-92 NXTSdZp6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3HYSGlEPTB;M{WuPVI4PyEQvF2= NIfsTI5USU6JRWK=
SKG-IIIa M4TYUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2TUfGlEPTB;M{[uNlU3OSEQvF2= NFTUcmVUSU6JRWK=
TE-11 M1vjNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXztUVNiUUN3ME2zOk42OjR|IN88US=> NGracHBUSU6JRWK=
SK-NEP-1 NGjkUW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYDEdWxEUUN3ME2zO{43PzR2IN88US=> NHn4TYlUSU6JRWK=
DB MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnjrTWM2OD1|Nz65NVg2KM7:TR?= NEK0U3VUSU6JRWK=
IA-LM M4Dt[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVr2c3FCUUN3ME2zPE4xOjN7IN88US=> MXPTRW5ITVJ?
COLO-829 MmjiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYLyN2t5UUN3ME2zPE41OTV7IN88US=> MXrTRW5ITVJ?
TGBC11TKB MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYf1WJhwUUN3ME2zPU4yPDB6IN88US=> NH31fWRUSU6JRWK=
CAL-51 NHHyRlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mme3TWM2OD12MD6wOlEzKM7:TR?= MWrTRW5ITVJ?
NCI-H2228 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXzIS5I{UUN3ME20NE4{PjZ{IN88US=> Ml2zV2FPT0WU
C32 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGPQdodKSzVyPUSwMlQxOjRizszN MYjTRW5ITVJ?
KU-19-19 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHfUN|dKSzVyPUSwMlc3QDNizszN MXXTRW5ITVJ?
KNS-62 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFe0eW1KSzVyPUSwMlg{QDFizszN NXTMO|Y1W0GQR1XS
FADU M1TUUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3vBV2lEPTB;NEGuNlUxOiEQvF2= NW\l[nRbW0GQR1XS
CAL-33 MkS0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWnabGhFUUN3ME20Nk43PzR7IN88US=> NEPTRWZUSU6JRWK=
CHP-134 NUn6WpM6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3f3bmlEPTB;NEKuPFQ6PiEQvF2= NGPkUZNUSU6JRWK=
HDLM-2 NXP4dYc6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWrJR|UxRTR{LkmwPFQh|ryP M3r1NXNCVkeHUh?=
NBsusSR MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkL6TWM2OD12Mz6wO|I2KM7:TR?= M3vXRXNCVkeHUh?=
SW954 M3\0eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{m3d2lEPTB;NEOuNVA2OyEQvF2= MlzqV2FPT0WU
HCC1806 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mne3TWM2OD12Mz60NVEh|ryP MXfTRW5ITVJ?
VMRC-RCZ NXPSZYpvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVrJR|UxRTR|LkS1PFYh|ryP MVnTRW5ITVJ?
A549 M{O3cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIf2PJZKSzVyPUSzMlk{OSEQvF2= NGjzTVdUSU6JRWK=
NKM-1 MkjnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3X1NmlEPTB;NEOuPVU2QCEQvF2= M1:4cnNCVkeHUh?=
DMS-273 NHrieVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MknCTWM2OD12ND63OVY4KM7:TR?= NIDPV3JUSU6JRWK=
TYK-nu NWixWI5sT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnziTWM2OD12NT6xNlM1KM7:TR?= NF3B[VhUSU6JRWK=
KALS-1 NWXuR5R2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4LjUWlEPTB;NEWuNVQ3KM7:TR?= NXfBcFhDW0GQR1XS
A101D NEfBOZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUHJR|UxRTR3LkS0OVYh|ryP MYTTRW5ITVJ?
G-361 NITwVY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{jnbWlEPTB;NE[uNlE{QCEQvF2= MX3TRW5ITVJ?
KARPAS-299 NGrLVY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYLJR|UxRTR4LkO1NVYh|ryP M{jHOXNCVkeHUh?=
RS4-11 M4W5emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYrJR|UxRTR4LkW0NkDPxE1? M3LZN3NCVkeHUh?=
HT-1376 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2\mVWlEPTB;NE[uO|QzPiEQvF2= NYLufI5zW0GQR1XS
SK-N-AS MlLpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFfvSnFKSzVyPUS2Mlc5OjJizszN NF6zWppUSU6JRWK=
MG-63 NInpSpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml;4TWM2OD12Nj65NFM3KM7:TR?= NYDj[WVOW0GQR1XS
EPLC-272H NEjyc5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVrJR|UxRTR4Lkm1NFMh|ryP MnHnV2FPT0WU
BALL-1 M1HzO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX3JR|UxRTR5LkizNkDPxE1? NUiy[|BRW0GQR1XS
LCLC-97TM1 M4jveWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWe3VpI3UUN3ME20PE4zODJizszN MV7TRW5ITVJ?
HO-1-N-1 NEjxS4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnTVTWM2OD12OD65Olc3KM7:TR?= MkT1V2FPT0WU
MFE-280 NFPaOIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWTJR|UxRTR7LkS2NVch|ryP M3zPU3NCVkeHUh?=
NCI-H526 NYGwPZBsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUfOSZVqUUN3ME20PU45OTZ|IN88US=> M2jtZ3NCVkeHUh?=
D-566MG MluxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF3yd45KSzVyPUS5MlkxQTZizszN MX3TRW5ITVJ?
BB30-HNC MmrxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFLaVFBKSzVyPUS5Mlk1QThizszN MX\TRW5ITVJ?
SK-N-DZ MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVTJR|UxRTVyLkC0PFEh|ryP M{jESHNCVkeHUh?=
HepG2  Ml\VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV:xNOKh|ryP Mn\yNlQhcA>? NIfreVFjdG:la4OgV2MuUUmLMz3pcoR2[2WmIGOgdIhie2ViYYLy[ZN1 MlnnNlU2OjdzMkO=
HepG2  NEiyc2pHfW6ldHnvckBCe3OjeR?= M2njclExyqEQvF2= MW[yOEBp Mkj3d5VxeHKnc4Pld{B1cGVicHjvd5Bpd3K7bHH0bY9veyCxZjDBWG0hd25iU3XyNVk5OSxiQ3jrNUBwdiCVZYKzOFUtKEOqa{Kgc44hXGi{NkisJIFv\CCFZHuyJI9vKFS7ckG1JIlv\HWlZXSgZpkhW0NvSVnJNy=> NEf5W2IzPTV{N{GyNy=>
KATO III  M2fRfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3Ho[VIvPS93L{euOUDPxE1? MoLpSG1UVw>? MYDlcohidmOnczD0bIUhfG:6aXPpeJkhd2Zib3zhdIFzcWJ? MYSyOFg1OTdzOB?=
hTCEpi MmnlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml:zNVAh|ryP MlzFSG1UVw>? NVTQTYszeHKndnXueJMhfGinIHP5eI9x[XSqaXOg[YZn\WO2IH;mJGhUXi1z NH;afpMzPDN5MEizOS=>
MCF10A M{\oNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2DmeVExKM7:TR?= MUKyOEBp MWrEUXNQ MXfwc5RmdnSrYYTld{B1cGViY4n0c5RwgGmlaYT5JI9nKEeD NInnfnkzPDF3MEW5OS=>
HL-60  NIfDbYpHfW6ldHnvckBCe3OjeR?= NEn5R2MyOCEQvF2= MlLwNE42KGh? NIWzeIlFVVOR NV7XdFFoemWmdXPld{BxcG:|cHjvdplt[XSrb36gc4YhS2itMtMg MkHXNlM6OzR2MUG=
MCF-7 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFrYS2UyNTFyMN88US=> NW\WW3dTOjRiaB?= NHziR2NHSlN? NXr4cXZIcW6qaXLpeJMhfGinIHPlcIwheHKxbHnm[ZJifGmxbh?= M3O4W|I{OTh3M{S3
HeLa  NXTIephFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHLjOoIyNTFyMN88US=> MniyNlQhcA>? NXzX[4tYTkKV MV7pcohq[mm2czD0bIUh[2WubDDwdo9tcW[ncnH0bY9v MUWyN|E5PTN2Nx?=
SH-SY5Y M{fhVGZ2dmO2aX;uJGF{e2G7 NXfZbGp4OTEEoN88UeKh M4jZTlI1KGh? M{LoTolvcGmkaYTzJINtcW:zdXnuc4wucW6mdXPl[EBxcG:|cHjvdplt[XSrb36gc4YheDV| NELQcGUzOjZ{N{K5OC=>
IMR-32 NGqzZVNHfW6ldHnvckBCe3OjeR?= MoTaNVDDqM7:TdMg M3zBRVI1KGh? MWPpcohq[mm2czDjcIlweXWrbn;sMYlv\HWlZXSgdIhwe3Cqb4L5cIF1cW:wIH;mJJA2Ow>? NUPXd|J2OjJ4MkeyPVQ>
A549 NX7uWGMyTnWwY4Tpc44hSXO|YYm= MUexNOKh|ryPwrC= M4K3d|EhcA>? MkLDd5VxeHKnc4Pld{BP[W6xLVPvMYlv\HWlZXSgdFU{KGGlY4XteYxifGmxbh?= NXfFc5p{OjJ3NUmzNlE>
T47D  NE\PZVZHfW6ldHnvckBCe3OjeR?= NF:5UVczOMLibV2= NWXNRZdFOjRiaB?= M2TuOWROW09? Mk\ydJJmfmWwdIOgTXIucW6mdXPl[EBl\We{YXTheIlwdiCxZjDJ{tpD|rF? NX;2R2kzOjFzNES4NFU>
A29 MEF M4LCO2Z2dmO2aX;uJGF{e2G7 NVWzWnpQOTEEoN88UeKh MoXUNYg> M2Dm[oJtd2Otc9MgeIhmKHCqb4PwbI9zgWyjdHnvckBw\iCDa4SgZZQhW2W{NEezxsA> MkGxNlAxPTN5OEG=
MDA-MB-453  NW\1[Ww3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXm1MVQxKM7:TR?= MWK3NkBp NFm3bmtKSzVyIH;mJFExKM7:TR?= NX;h[o95OjByNUO3PFE>
PC-3 NETSV5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1;rPVUuPDBizszN NI\0UXo4OiCq MVnJR|UxKG:oIEGwJO69VQ>? M1H5V|IxODV|N{ix

... Click to View More Cell Line Experimental Data
Assay
Methods Test Index PMID
Western blot
p-AKT(Ser473) / p-AKT(Thr308); 

PubMed: 22739265     


Cells were serum-starved for 6 h and treated with KU-55933 (10 µmol/L) for 1 h before treatment with insulin (100 nmol/L) for 45 min. Cells were lysed, and cell lysates were subjected to SDS-PAGE and Western blotting for the detection of phospho-Akt at Se䲧疝Ỵ疞㧀疜膉痘 瘿�෋ᾰƌ෋à 㺣痖

PARP / Cleaved PARP / Caspase-3 / Cleaved caspase-3 ; 

PubMed: 22739265     


ATM inhibition by KU-55933 induces apoptosis in differentiated but not undifferentiated SH-SY5Y cells. Cells were starved for 6 h in serum-free medium. KU-55933 (10 µmol/L) was added 1 h before insulin (100 nmol/L) treatment. After 3 h of insulin stimulat䲧疝Ỵ疞㧀疜膉痘 瘿�෋ᾰƌ෋à 㺣痖帉痖Ѐ瑖堘𢡄빢᎒෋à鑸᎒彿堙奋堙巫堙᎒ﻺ᎒彿堙ﻮ᎒塚堙ﻺ᎒ꍈ堞빢᎒學堙漸堞圔堙빢᎒圞堙圭堙𢡄玚Wᾰƌ ᾰƌ戤

ATM-S1981 / ATM / p-p53(S15) / p53 ; 

PubMed: 20639198     


Antioxidant and ATM inhibitors blocked phosphorylation of ATM-S1981, Akt-S473, and p53-S15 as stimulated by H2O2 exposure. Cells were treated with 100 μm H2O2 for 30 min in the absence or presence of KU-55933. Whole cell lysates were subjected to Western 䲧疝Ỵ疞㧀疜膉痘 瘿뾠ՂᾰƌՂĀ 㺣痖

p21 / p27 / p53 ; 

PubMed: 20177072     


HMGE cells were incubated for the indicated times with 1 μm KU-55933 or DMSO. Total protein extracts were analyzed by Western blotting for p21WAF1/CIP1, p27KIP1, p53, or β-actin.

22739265 20639198 20177072
Immunofluorescence
p-S824 KAP1 / ZEBRA ; 

PubMed: 28249048     


HH514-16 cells were treated with NaB (upper panel) or NaB plus KU-55933 (1μM; middle panel) or NaB plus Torin1 (0.5μM; lower panel) for 24 hours and stained with anti-phospho KAP1 (S824) plus anti-ZEBRA antibodies and visualized at 1000X magnification.

28249048
体内研究 KU-55933抑制ATM依赖的STAT3激活，通过上调DR5表达增强TRAIL调节的凋亡,抑制STAT3 和NF-κB都和下调cFLIP有关，伴随着凋亡水平上升。ATM抑制剂KU-55933 影响TRAIL调节的凋亡的效果比JAK2抑制剂AG490或STAT3β过量表达都高。[3]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验：

[1]
- 合并

纯化的酶实验:

通过免疫沉淀反应从HeLa核蛋白萃取中获得用于体外研究的ATM，在反应buffer中，把兔多克隆抗血清加到ATM羧基端第400个氨基酸处，buffer包含25 mM HEPES (pH为7.4), 2 mM MgCl2, 250 mM KCl, 500 μM EDTA, 100 μM Na3VO4, 10% v/v 甘油, 及0.1% v/v Igepal。和蛋白A凝胶温育1小时，然后进行离心作用，从核蛋白中分离ATM抗体复合物。在96孔板中，包含ATM的凝胶珠和1 μg 底物GST-p53N66 (p53的氮端第66位氨基酸与GST融合)在ATM实验buffer中37oC下温育，buffer包括25 mM HEPES (pH 为7.4), 75 mM NaCl, 3 mM MgCl2, 2 mM MnCl2, 50 μM Na3VO4, 500 μM DTT, 及5% v/v甘油。震荡10分钟后，加入ATP，最终浓度为50 μM，在37oC反应持续1小时。按250×g转速4oC下离心10分钟，除去ATM凝胶珠，上清液转移到96孔板上，在室温下温育1.5小时。然后用PBS冲洗，烘干，加入p-p53(Ser15)抗体用于ELISA分析。使用增强的化学发光溶液产生信号和化学发光。
细胞实验：

[1]
- 合并
  • Cell lines: U2OS细胞
  • Concentrations: 10 μM
  • Incubation Time: 2小时
  • Method:

    U2OS细胞经过电离辐射(3, 5, 或15 Gy) 或者UV处理(5或50 J/m2)，通过p-p53（Ser15）和p53 的Western blot分析而测定ATM反应。在不同时间点获得细胞萃取物，SDS-PAGE分离蛋白，加入p-p53(Ser15)抗体，ATM增多。加入p53抗体观察到p53随着时间变化趋于稳定。为了测定KU-55933的IC50值，使用p-p53(Ser15)抗体检测KU-55933抑制ATM的效果。KU-55933加到细胞中，预温育1小时，然后进行电离辐射。在体外，使用扫描密度测定法测定IC50值。


    (Only for Reference)
动物实验：

[3]
- 合并
  • Animal Models: 携带LU1205细胞的BALB/c nu/nu鼠
  • Dosages: 10 μM
  • Administration: --
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 33 mg/mL (83.44 mM)
Water Insoluble
Ethanol Insoluble
体内 从左到右依次将纯溶剂加入产品，现配现用(数据来自Selleck实验检测而非文献)：
5%DMSO+40%PEG300+5%Tween80+50%ddH2O
 3.95 mg/mL

* 溶解度检测是由Selleck技术部门检测的，可能会和文献中提供的溶解度有所差异，这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 395.49
化学式

C21H17NO3S2
CAS号 587871-26-9
储存条件 粉状
溶于溶剂
别名 N/A

动物体内配方计算器 (澄清溶液)

第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量）
给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 ul 动物数量 只
第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系Selleck为您提供正确的澄清溶液配方）
% DMSO % % Tween 80 % ddH2O
计算重置

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系，公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液，使用的计算公式为：

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量：

总分子量：g/mol

注：化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

技术支持

在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题，请给我们留言。

  • * 必填项
Selleck产品目录册

ATM/ATR Signaling Pathway Map

ATM/ATR Inhibitors with Unique Features

相关ATM/ATR产品

  • Ceralasertib (AZD6738) New

    Ceralasertib (AZD6738) 是一种口服具有活性的，选择性 ATR 激酶抑制剂，IC50 为 1 nM。Phase 1/2。

  • CHIR-99021 (CT99021) New

    CHIR-99021 (CT99021)是一种GSK-3α和GSK-3β抑制剂， IC50分别为10 nM and 6.7 nM。CHIR99201对CDKs没有交叉反应性，对GSK-3β的选择性是对CDKs选择性的350倍。CHIR-99021 可作为Wnt/β-catenin的激活剂并诱导自噬。

  • Dorsomorphin (Compound C) New

    Dorsomorphin (Compound C, BML-275)是一种有效的，可逆选择性 AMPK 抑制剂，无细胞试验中 Ki 为 109 nM，对几个结构相关的激酶，包括ZAPK，SYK，PKCθ，PKA，和 JAK3没有显著的抑制作用。 也会抑制 I型BMP receptors ALK2，ALK3和ALK6 的活性。Dorsomorphin被应用于促进特定细胞分化和诱导癌细胞自噬。

  • VE-821

    VE-821是一种有效的，选择性的，ATP竞争性ATR抑制剂，在无细胞试验中Ki/IC50为13 nM/26 nM，抑制H2AX磷酸化，对PIKKs ATM， DNA-PK， mTOR和PI3Kγ具有很低的抑制活性。

  • KU-60019

    KU-60019是一种改进的KU-55933类似物，在无细胞试验中作用于ATM，IC50为6.3 nM，作用于ATM比作用于DNA-PK和ATR的选择性分别高270和1600倍，并且是高度有效的放射增敏剂。

    Features:KU-60019是KU-55933改善的类似物, 更加有效阻断ATM调节的DDR活动。

  • Berzosertib (VE-822)

    Berzosertib (VE-822, VX970, M6620)是一种ATR抑制剂，在HT29细胞中IC50 为 19 nM。

  • Chloroquine diphosphate

    Chloroquine diphosphate是一种4-氨基喹啉的抗疟疾和抗风湿药，也是一种ATM激活剂。Chloroquine 也是一种toll-like receptors (TLRs)的抑制剂。

  • AZ20

    AZ20是一种新型有效的选择性ATR激酶抑制剂，无细胞试验中IC50为5 nM，比作用于mTOR的选择性高8倍。

  • CP-466722

    CP-466722是一种有效的，可逆的ATM抑制剂，不影响ATR，且抑制PI3K或PIKK家族成员。

  • ETP-46464

    ETP-46464是一种有效的，选择性ATR抑制剂，IC50为25 nM。

Tags: 购买KU-55933 (ATM Kinase Inhibitor) | KU-55933 (ATM Kinase Inhibitor)供应商 | 采购KU-55933 (ATM Kinase Inhibitor) | KU-55933 (ATM Kinase Inhibitor)价格 | KU-55933 (ATM Kinase Inhibitor)生产 | 订购KU-55933 (ATM Kinase Inhibitor) | KU-55933 (ATM Kinase Inhibitor)代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID